Objective-Patients with systemic lupus erythematosis are at risk for premature atherosclerosis and half of the patients with systemic lupus erythematosis have elevated type I interferon (IFN-I) levels. We hypothesized that IFN-I would induce premature atherosclerosis by increasing the number of smooth muscle progenitor cells (SMPC) in the bloodstream and promoting atherosclerotic lesions within the vasculature. Approach and Results-SMPC isolated from wild-type and IFN receptor knockout animals were cultured in medium±IFN-I.
D uring the past 20 years, considerable progress has been made in prolonging the life of patients with systemic lupus erythematosis (SLE). However, this progress has not resulted in a proportional decrease in the number of patients with SLE dying from cardiovascular disease. Individuals with SLE have an increased risk of coronary heart disease, [1] [2] [3] are at least 2× more likely, than their healthy counterparts, to be hospitalized for an acute myocardial infarction, and are nearly 4× more likely to be hospitalized for chronic heart failure. 4 Patients with SLE are at risk for premature atherosclerosis that is not fully explained by standard Framingham risk factors 5, 6 ; additional factors related either to the disease process itself or to its treatment are thought to be instrumental in the acceleration of atherosclerosis. 7, 8 
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Although the pathogenic mechanisms of premature atherosclerosis in SLE are unclear and likely involve multiple pathways, recent evidence indicates that type I interferon (IFN-I) has profound effects on bone marrow (BM) progenitor angiogenic cells that could contribute to the risk of development of atherosclerosis in SLE. 9, 10 However, the effect of IFN-I on the other major component of the artery wall, smooth muscle cells (SMC), and by extension smooth muscle progenitor cells (SMPC), 11, 12 has not been studied.
Although some studies suggest that SMPC are of monocyte/macrophage lineage and may not differentiate into definitive SMC, 13, 14 it has been hypothesized that the BM-derived SMPC are involved in the development of atherosclerosis. 15 However, it is unclear whether SMPC accelerate or repress atherosclerosis; whereas a recent study found that SMPC could stabilize atherosclerotic lesions, 16 another study concluded that an increase in SMPC may contribute to accelerated atherosclerosis. 17 In addition, the origin of SMPC is highly controversial. Traditional studies of atherosclerosis provided evidence that intimal lesions were polyclonal and derived from medial SMC that initiated DNA replication. 18 Interestingly, a recent study suggested circulating SMPC participated the development of atherosclerosis, 19 whereas the vascular wall, particularly the adventitia, is an alternative source of SMPC. 20 Adequate understanding the role of SMPC during the atherosclerotic progress is critical in developing new avenues for potential therapy.
In this study, we tested the hypothesis that IFN-I would increase the number of SMPC and maintain the SMPC in an immature phenotype both in vitro and in vivo. In vitro, to test our hypothesis, we cultured SMPC in different culture media. In vivo, we developed a novel, mouse model of chronic expression of IFN-I. In our model, electroporation of a plasmid encoding IFN-I into the posterior thigh muscle of a mouse led to IFN-I expression for >3 months. Increased SMPC colony numbers were observed from peripheral blood within mice that expressed IFN-I when compared with control mice. More interestingly, significant preatherosclerotic-like lesions were observed within the vasculature compared with control animals. Within these lesions, cells expressing CD34 and SM-α-actin, but not SM myosin heavy chain (SM-MHC) were detected.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
We sought to study the in vitro effect of IFN-I on cultured SMPC colony number. After 14 days in culture, we routinely observed the appearance of spindle-shaped cells, SMPC colonies ( Figure 1A ). When peripheral blood mononuclear cells, isolated from 4-month-old wild-type (WT) mice, were exposed to IFN-I during the culturing of the colonies, the number of SMPC colonies significantly increased by 54% when compared with colonies cultured in vehicle (1.54±0.16 versus 1.00±0.10 P=0.01). However, when peripheral blood mononuclear cells, isolated from IFN receptor knockout animals, were exposed to IFN-I, there was no difference in the number of colonies when compared with vehicle (P=0.33; Figure 1B ). Similar results were observed when the blood of older, WT mice (10 months old) were treated with IFN-I or vehicle (1.80±0.22 versus 1.00±0.13 P=0.006).
Immunohistochemical staining of the SMPC colonies demonstrated that the majority of the cells within the SMPC colonies expressed SM-α-actin and only a portion of the cells coexpressed SM-MHC. Interestingly, the ratio of MHC/ SM-α-actin in IFN-I-treated SMPC was significantly lower than cells treated with vehicle (32.8% versus 54.4%, P=0.02; Figure 1C -1H).
One-way ANOVA analysis indicated that there was no significant difference in the expression of non-SMC markers (CD14, CD36, F4-80, and CD34) after 2 weeks culture within the different culture media, although the expression of CD14, CD36, and CD34 slightly increased after treatment of IFN-I and the expression of CD34 after treatment of transforming growth factor-β (TGF-β) slightly decreased ( Table I in the online-only Data Supplement). Real-time polymerase chain reaction results demonstrated that the mRNA level of SM-α-actin, SM-MHC, and SM22 was upregulated 4.25-, 1.01-, and 75.4-fold after treatment of IFN-I, respectively; but, the mRNA level of calponin decreased 0.33-fold. However, after treatment of TGF-β, all mRNA levels were downregulated except for SM22 ( Table II in the online-only Data Supplement).
To demonstrate the long-term expression activity of the IFN-I plasmid after electroporation, we measured surface expression of the interferon-inducible protein stem cell antigen-1 (also known as Ly6A) on B lymphocytes. Compared with control plasmid (β-galactosidase), electroporation of a plasmid encoding IFN-α5 lead to a significant increase in stem cell antigen-1 levels as early as 1 day after injection ( Figure 2A ). Marked elevation of stem cell antigen-1 persisted for at least 4 months after electroporation ( Figure 2B ). Meanwhile, X-gal staining indicating the β-galactosidase plasmid was transduced successfully can be seen in the muscle at the time of euthanization ( Figure 2C ).
To evaluate the effect of IFN-I on SMPC numbers in vivo, we cultured peripheral blood mononuclear cells for SMPC colony numbers from WT animals 3 weeks after electroporation with either an IFN-I or the β-galactosidase, control plasmid. The colony number was significantly higher in the peripheral blood mononuclear cells isolated from mice electroporated with the IFN-I plasmid when compared with the control plasmid (14.4±2.3 versus 5.3±1.7, P=0.007; Figure 2D ). Twenty 7-month-old mice were electroporated with the IFN-I or control plasmid and followed for 3 months. One mouse died from uncertain cause (no obvious abnormality was observed at autopsy) in the group electroporated with IFN-I plasmid, and no mice died in the control plasmid group. In mice injected with the control plasmid, only 45% had any thickening of the abdominal, aortic bifurcation ( Figure 3A and 3B). However, 78% of mice in the IFN-I plasmidinjected group had thickening of the abdominal aortic bifurcation, and the size of the lesions were significantly larger than the mice injected with the control plasmid (230.4±69.0 μm 2 versus 46.4±17.5 μm 2 , P=0.011; Figure 3C ). More interestingly, preatherosclerotic-like lesions only were found in the IFN-I plasmid-injected mice, although the total length of most lesions was less than ≈500 μm. These preatherosclerotic-like lesions were located at the original internal elastic lamina and they were composed of several layers of SMC separated by a duplicated elastica ( Figure 3D-3G ). However, there was no significant difference in media thickness (13.7±0.8 μm versus 11.8±0.6 μm, P=0.104) and cell the control plasmid-treated animals, no CD34-positive cells were detected in the lesions (Figure 4F-4I) .
Meanwhile, interrupted CD31 staining was observed within 77.8% IFN-I-treated mice and 37.5% control mice ( Figure 4J and 4K ). In addition, the percentage of interrupted endothelium in IFN-I-treated animals was significantly greater than in control animals (1.64±0.38% versus 0.38±0.22%, P=0.015). Although Pearson correlation coefficient and subsequent significance testing indicated a relationship between endothelial cell damage and preatherosclerotic-like lesion in all mice, there was no significant difference between IFN-I-treated animals and control animals. There was also no significant lesions in IFN receptor knockout animals that underwent electroporation with either IFN-I or control plasmid ( Figure I in the online-only Data Supplement).
Unexpectedly, immunohistochemical staining did not detect any signal for F4/80, CD45, CD3, and tenascin-C within any of the preatherosclerotic-like lesions (data not shown).
Discussion
After the identification of BM progenitor angiogenic cells in human peripheral blood in 1997, 21 the first report of the ability of circulating progenitor cells to differentiate into SMC was published in 2002. 11 The role of circulating SMPC on vascular diseases, such as atherosclerosis and neointima formation after injury still remains controversial. Although BM-derived SMPC have been detected in human atherosclerotic tissue and animal models of vascular disease, it is still unknown whether the SMPC serve to accelerate or decelerate the development of vascular lesions. 12 Elevated serum levels of IFN-I in patients with SLE were first reported over 3 decades ago, 22 and SLE is associated with a significant increase in atherosclerotic, cardiovascular complications. 2 Several studies suggest that BM progenitor angiogenic cells become dysfunctional on exposure to IFN-I, 9, 10 which may exacerbate the development of atherosclerosis in SLE. However, the effect of IFN-I on SMPC and its subsequent effect on premature atherosclerosis in SLE is unknown.
In our study, the numbers of SMPC colonies were significantly increased after in vitro treatment of peripheral blood mononuclear cells with IFN-I. In addition, in vitro IFN-I treatment decreased the expression ratio of SM-MHC/SMα-actin, perhaps via the upregulation SM-α-actin mRNA. SM22 is one of the earliest markers of differentiated SMC, 23 and in our study was surprisingly upregulated after treatment with IFN-I. Furthermore, the level of calponin was downregulated, which suggests that SMPC might be maintained in a more immature state and possess a higher ability to proliferate in the presence of IFN-I. 24 Meanwhile, flow-activated cell sorting results demonstrate that after culturing the majority of cells were SMC.
The platelet-derived growth factor is a key cytokine for propagating SMPC in vitro, having been used to culture these cells for 2.5 days to 2 weeks. 25 In our study, we added it to our media only during the first week of SMPC culture. To evaluate the effect of IFN-I on SMPC phenotype in the presence of a SMC differentiating cytokine, we added TGF-β to the culture media after the first week. Surprisingly, all SMC markers, except SM22, were downregulated by culturing in TGF-β. Previously, when TGF-β was added to the culture media of SMC harvested from vessels, the expression of most SMC differentiation marker genes, including SM-α-actin, SM-MHC, calponin, and SM22, were upregulated. 26 With regard to SMPC isolated from peripheral blood, the coadministration of TGF-β and IFN-I led to an upregulation of SM22 and SM-α-actin, whereas calponin and SM-MHC were downregulated. This suggests that IFN-I induces a different expression pattern in immature SMC when compared with mature SMC.
IFN-I is a superfamily and has dozens of subtypes. However, all of the subtypes do not fully diverge and they bind to the same receptor. Interestingly, some IFN-I subtypes (IFN-α4, IFN-α11, IFN-α12 , IFN-β, and limitin) demonstrate a higher biological activity levels when compared with others, whereas IFN-α7 and IFN-α10 exhibit a lower activity. 27 We chose IFN-α5 in our study as an intermediary subtype and speculated the other subtypes might possess a similar capacity. The exact molecular mechanism for the increased SMPC colony formation by IFN-I is still under investigation.
However, a recent study provided mechanistic evidence that IFN-I, via the IFN-I receptor, upregulates the production of endothelin-1. 28 Endothelin-1 has multiple and complex effects on SMC and the development of atherosclerosis. 29, 30 IFN-I also has been shown to increase the expression of chemotactic receptors and ligands (CCR5 and CCL5) on BM macrophages. 31 Eccentric lesions of intimal thickening are an early lesion in the pathogenesis of atherosclerosis. Although intimal thickening is observed in primate models, it is difficult to induce them in commonly used strains of WT rodent models. 32 Only 8±3% of the aortas of WT mice have lesions even after 9 months on a Western diet. 33 In this study, we demonstrated that after 3 months exposure to IFN-I on regular mice chow, preatherosclerotic-like lesions were clearly visible at the bifurcation of the abdominal aorta, a site prone to atherosclerosis. Compared with mice of a 129sv genetic background, C57BL mice are more resistant to the formation of atherosclerosis lesions and the aortic bifurcation is less sensitive to atherosclerosis as compared to the aortic root/arch. 34, 35 IFN-I is likely to produce more aggressive lesions in locations that are more sensitive to develop atherosclerosis. A recent report demonstrated that IFN-I modulates atherosclerosis lesion progression in lupus-prone and dual knockout of apolipoprotein E and IFN-I receptor murine models on a Western diet. 36 Our model provides further insight into the relationship of elevated IFN-I levels and atherosclerosis even in WT animals fed normal chow, particularly, in female animals because lupus is more common in women.
Macrophage infiltration is thought to be another critical step in the development of classic atherosclerosis. However, we could not detect any F4/80 and CD45 cells within the preatherosclerotic-like lesions. Interestingly, we found cells expressing both SM-α-actin and CD34, but not SM-MHC. The literature suggests these might be SMC-like macrophages or macrophage-like SMCs within atherosclerotic lesions. 37 Unfortunately, there is no specific marker to precisely differentiate an immature SMC from a macrophage. 37 Our previous study demonstrated that IFN-I modulated the recruitment of monocytes and contributed to chronic inflammation in atherosclerosis, 38 which has been replicated. 31 These monocytes/macrophage may be able to mature into SMC-like macrophages or macrophage-like SMCs and contribute to the development of atherosclerosis, particularly, in lupus patients with elevated levels of IFN-I.
Because of the technical limitations, we were unable to follow >4 labels within a single-tissue section and the size of lesions limited sufficient slices for further immunohistochemical analysis. We hypothesize that IFN-I can promote SMPC differentiation and in the absence of other atherosclerosispromoting factors, these SMPC, under the influence of IFN-I, maintain a progenitor cell state. However, if these SMPC are exposed to other atherosclerosis-promoting factors, such as a Western diet or an apolipoprotein E disturbance, these SMPC may have the ability to differentiate along a macrophage lineage (and subsequent foam cells), as occurred in apolipoprotein E mice exposed to IFN-I. 36 Further study in atherosclerosis-prone animals, like the apolipoprotein E knockout mice, would allow the development of larger lesions, which would permit a more detailed analysis of the cellular components of the lesions.
Our study also raises the question as to the source of the cells expressing SM-α-actin and CD34 within the preatherosclerotic-like lesions. These cells may be derived from dedifferentiated cells from the vasculature or may be derived from circulating SMPC; these circulating cells could penetrate the vessel wall at sites of endothelial injury at atherosclerosis-prone areas. Interestingly, Tang et al 39 reported that there were SM-α-actin positive only cells in the vessel media, which might contribute to the development of atherosclerosis. Hu et al 40 also demonstrated that adventitia origin of progenitor cells might play an important role within artherosclerotic lesion. Although the media thickness and cell density were not significantly changed after preliminary analysis in our current study, we could not rule out the potential effect of IFN-I on local SMPC from the vessel wall (particularly, after the endothelium was damaged because of IFN-I) and their contribution to the development of atherosclerosis. Further studies are needed to differentiate between these 2 possibilities, like within BM chimeric animal. Whatever the source, a recent study demonstrated that targeting SM-α-actin and CD34-expressing cells could inhibit intimal hyperplasia and promote regenerative repair of the artery. 41 Thus, targeting these SM-α-actin and CD34positive cells may be a potential treatment to prevent atherosclerosis, this may be especially relevant in patients with lupus with elevated levels of IFN-I.
In our study, control animals had minor levels of intima thickening and damage to the integrity of endothelium. We think that this is an age-related lesion because the animals were 10 months old when they were euthanized. However, significantly larger intima thickening and preatherosclerotic-like lesions were observed in IFN-I-treated animals accompanied by more severe damage of the endothelium. Interestingly, further Pearson correlation coefficients analysis indicated that the relationship between endothelium damage and preatherosclerosis-like lesion was not significantly different in IFN-I-treated animals and control animals, although there was positive relationship between the preatherosclerotic-like lesions and endothelium damage in all mice. It suggests that if we consider that IFN-I essentially accelerated natural occurring age-related atherosclerosis, under specific circumstances, atherosclerotic-like lesion can occur before overt endothelial injury or the repair ability of endothelial progenitor cells still could compensate the damage at early stage of the development of IFN-I-related atherosclerosis. Our findings with regard to the damage of endothelial cells because of IFN-I was in accordance with our 10 and others 42, 43 previous reports.
Other key components in the development of atherosclerosis are T cells and tenascin-C, 44, 45 none of which we detected in the IFN-I-induced preatherosclerotic-like lesions. The lack of these elements suggests that these lesions might be early, stage in the development of lupus-related atherosclerosis, before the stage when T cells are recruited or tenascin-C is expressed.
In summary, we have examined the effect of IFN-I exposure on SMPC in vivo and in vitro. Using our novel model, we describe the effect of IFN-I on the development of early stage atherosclerotic-like lesion at atherosclerotic-prone sites within the WT animal vasculature. Although circulating SMPC was considered a protective role in atherogenesis, 46 our data suggest that IFN-I may prevent the full maturation of SMPC into smooth muscle cells. Furthermore, this immature state may be more prone to differentiation along the macrophage line and results in a less matured SMC within fibrous cap. Both could lead to the development of a plaque that is more likely to undergo rupture. Our data in combination with other published studies suggest a complex interplay between IFN-I and other atherosclerotic factors in SMC maturation, which contributes to the accelerated atherosclerosis in patients with SLE.
